Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports June 14, 2022
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses April 6, 2022
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1 March 22, 2022
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1 March 10, 2022
Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript March 3, 2022
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum January 26, 2022
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant December 20, 2021
